H.C. Wainwright lowered the firm’s price target on Oncternal Therapeutics to $19 from $28 and keeps a Buy rating on the shares post the Q1 report. The analyst cites the company’s additional equity financings in the future for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics reports Q1 EPS ($2.83), consensus ($2.88)
- Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
- Oncternal Therapeutics reports inducement award under Nasdaq listing rule
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- ONCT Earnings this Week: How Will it Perform?